Glenmede Trust’s Forte Biosciences FBRX Stock Holding History

Glenmede Trust’s Portfolio FBRX Stock Details FBRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-100	Closed	-$407	–	3098
2019 Q1	$407	Sell	100 -2	-2%	-$7.73K	﹤0.01%	943
2018 Q4	$314	Buy	+102	New	+$439K	﹤0.01%	970
2018 Q3	–	Sell	-13	Closed	-$47K	–	1574
2018 Q2	$47K	Hold	13	–	–	﹤0.01%	1463
2018 Q1	$51K	Hold	13	–	–	﹤0.01%	1621
2017 Q4	$51K	Buy	+13	New	+$51.9K	﹤0.01%	1621

Other funds holding FBRX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

SAM

Sectoral Asset Management Montreal, Quebec, Canada $121M AUM 73.47% 1-Year Est. Return

FCMI

Foresite Capital Management III Larkspur, California $37.9M AUM 6.87% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

6CM

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

Glenmede Trust's FBRX Position: Q2 2019 in Review

Glenmede Trust sold out of Forte Biosciences (FBRX) in Q2 2019, closing a stake of 100 shares — an estimated $407 sold.

Glenmede Trust first reported a position in FBRX in Q4 2017 and held it in 5 quarters. The position peaked at $51K in Q1 2018. 74 funds tracked by Wall St. Rank hold FBRX as of Q2 2019.

Glenmede Trust reported no remaining Forte Biosciences position as of Q2 2019 after selling out during the quarter.
Glenmede Trust sold 100 Forte Biosciences shares in Q2 2019, an estimated $407.
Glenmede Trust first reported a position in Forte Biosciences in Q4 2017 and held it in 5 quarters.
Glenmede Trust's Forte Biosciences position peaked at $51K in Q1 2018.
74 funds tracked by Wall St. Rank held Forte Biosciences as of Q2 2019.

Based on Glenmede Trust's 13F filing for Q2 2019, filed 13 Aug 2019.